Future multisite trials integrating molecular profiling (e.g., albumin binding assays) and multidimensional sedation metrics (e.g., Stop-Bang scoring) should: 1) validate thresholds in frail elderly and acute respiratory distress syndrome(ARDS) cohorts, 2) elucidate concentration-dependent cellular transport mechanisms, and 3) optimize combinatorial monitoring frameworks that balance analytical precision with clinical workflows. The gene discussed is ALB; the disease is acute respiratory distress syndrome.